Results 21 to 30 of about 136,428 (330)

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1

International Journal of Endocrinology, 2015
The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels.
XingChun Wang, Huan Liu, Jiaqi Chen, Yan Li, Shen Qu   +4 more
doaj   +1 more source

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice

Journal of Cardiovascular Development and Disease, 2023
Background: Calcific aortic valve disease (CAVD) is a significant cause of morbidity and mortality among elderly people. However, no effective medications have been approved to slow or prevent the progression of CAVD.
Yangzhao Zhou, Zhaoshun Yuan, Min Wang, Zhiyuan Zhang, Changming Tan, Jiaolian Yu, Yanfeng Bi, Xiaobo Liao, Xinmin Zhou, Md Sayed Ali Sheikh, Dafeng Yang   +10 more
doaj   +1 more source

Intra-islet glucagon-like peptide 1 [PDF]

Journal of Diabetes and its Complications, 2016
Glucagon-like peptide-1 (GLP-1) is originally identified in the gut as an incretin hormone, and it is potent in stimulating insulin secretion in the pancreas. However, increasing evidence suggests that GLP-1 is also produced locally within pancreatic islets.
Genevieve E. Fava, Emily W. Dong, Hongju Wu   +2 more
openaire   +2 more sources

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. [PDF]

, 2015
© 2015 The Authors.Objective: Although Glucagon-like peptide 1 is a key regulator of energy metabolism and food intake, the precise location of GLP-1 receptors and the physiological relevance of certain populations is debatable.
Cork, SC, Gribble, FM, Holt, MK, Reimann, F, Richards, JE, Trapp, S   +5 more
core   +2 more sources

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists [PDF]

, 2014
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a ...
Andrei C Sposito, Francisco Kerr Saraiva
core   +1 more source

How glucagon-like is glucagon-like peptide-1? [PDF]

Diabetologia, 1984
Although glucagon-like peptide-1 has the appearance of a glucagon-homologue that may be co-secreted with glucagon, synthetic glucagon-like peptide-1-(1-37) does not significantly affect plasma glucose and insulin concentrations when administered at high doses (100 and 400 micrograms) to cortisone-pretreated rabbits.
M, Ghiglione, L O, Uttenthal, S K, George, S R, Bloom   +3 more
openaire   +2 more sources

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors

Physiological Reports, 2017
Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone increasing postprandial insulin release. GLP‐1 also induces diuresis and natriuresis in humans and rodents. The GLP‐1 receptor is extensively expressed in the renal vascular tree in normotensive rats
Jonas Ronn, Elisa P. Jensen, Nicolai J. Wewer Albrechtsen, Jens Juul Holst, Charlotte M. Sorensen   +4 more
doaj   +1 more source

Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning [PDF]

, 2016
This work was supported by the British Heart Foundation (Ref: RG/14/4/30736), Medical Research Council (MR/N02589X/1) and The Wellcome Trust (Ref: 200893/Z/16/Z). A.V.G. is a Wellcome Trust Senior Research Fellow. S.M.
Aleksander Mrochek, Alexander V. Gourine, Ana Gutierrez del Arroyo, Andrey Gourine, Barragán, Gareth L. Ackland, Gourine, Göke, Jenifer Sanchez, John Pernow, Marina V. Basalay, Per-Ove Sjoquist, Svetlana Mastitskaya, Uitterdijk   +13 more
core   +2 more sources

Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition

World Nutrition, 2019
There has been significant research and development in pharmaco-therapeutic molecules for management of type 2 diabetes mellitus (T2DM). Diabetes specific nutrition intervention & newer incretin-based therapies have gained a lot of attention.
ANSHU JOSHI, SAMEER RAO, GANESH KADHE
doaj   +1 more source

Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells [PDF]

Endocrinology and Metabolism, 2014
BackgroundGlucagon-like peptide 1 (GLP-1), an incretin hormone well known for its glucose-lowering effect, was recently reported to exert an anabolic effect on bone. Although the exact mechanism is not known, it likely involves the GLP-1 receptor (GLP-1R)
Yun Kyung Jeon, Min Jung Bae, Ju In Kim, Joo Hyoung Kim, Soo Jong Choi, Su Kyoung Kwon, Joon Hyop An, Sang Soo Kim, Bo Hyun Kim, Yong Ki Kim, In Joo Kim   +10 more
doaj   +1 more source